A new edition of Kern Pharma’s charity initiative, ‘A Hug for Alzheimer’s’, is underway

• Previous editions have raised over €20,000, which has been donated to the Ace Alzheimer Center Barcelona foundation
• This initiative aims to raise awareness of the disease and support people with Alzheimer’s, their families and carers
• For every photograph uploaded to Instagram or the ‘Un abrazo por el Alzheimer’ website, the company will donate €2 to research projects and patient support initiatives

Barcelona, 8 September 2025 – For the fifth consecutive year, Kern Pharma, the pharmaceutical company of the Indukern Group, is promoting the charity initiative ‘A Hug for Alzheimer’s’ as part of World Alzheimer’s Day, which is celebrated on 21 September. The campaign began on 1 September and will run until 2 October, coinciding with Alzheimer’s Night, a charity event organised by Ace Alzheimer Center Barcelona, where music, culture, art and humour will take centre stage and the importance of research will be highlighted. This charity initiative aims to raise awareness of the need for more research and support for people with Alzheimer’s. In Spain, between 30% and 40% of cases remain undiagnosed, and one in two people has a direct or indirect connection to this disease. Hugs on social media or on the website unabrazoporelalzheimer.com Anyone wishing to join this charity campaign can do so very easily: by uploading as many photos as possible of themselves giving a hug to the website unabrazoporelalzheimer.com, or by tagging @kern_pharma on Instagram with the hashtag #unabrazoporelalzheimer. For every photo uploaded to Instagram or the website, Kern Pharma will donate €2 to the Ace Alzheimer Center Barcelona so that they can continue their work and research, supporting those living with this condition. Over the past four editions, more than €20,000 has been raised, which was allocated to the association’s various projects. This charity campaign forms part of Kern Pharma’s commitment to improving the quality of life of people with Alzheimer’s, by developing various initiatives that help raise awareness of the condition and provide support to those living with it. A notable example is the www.konexionalzheimer.com platform, a digital space offering reliable information to answer questions about the disease. Through this initiative, the company actively contributes to the Sustainable Development Goals (SDGs), specifically Goal 3 on Good Health and Well-being, as well as Goal 17 on Partnerships for the Goals. About Kern Pharma Kern Pharma is a pharmaceutical company with over 25 years of history, forming part of the family-owned Indukern Group. It currently has a product portfolio of 269 products in 764 different formulations. Kern Pharma’s business revolves around five key areas: generic and prescription medicines, self-care, biosimilars, women’s health products under the Gynea brand, and sports nutrition under the Finisher® brand. It is currently the third-largest pharmaceutical company in terms of units sold in Spanish pharmacies and the fourth-largest in the hospital sector. The company currently employs a team of 984 people who work tirelessly to provide the best solutions for patients and healthcare professionals. Headquartered in Terrassa (Barcelona), with its own production plants in Terrassa and Alcantarilla (Murcia), and offices in Madrid, Kern Pharma is organised into eight main areas that enable it to successfully meet the challenges of the future: Operations; Sales and Marketing; International; Scientific and Technical; Business Development; Quality; Human Resources; and Finance and Information Systems. It also has two subsidiaries, one in Portugal and the other in the United States. In terms of sustainability, Kern Pharma contributes to the achievement of the Sustainable Development Goals (SDGs) by providing decent, safe work with fair pay, forming partnerships with NGOs that assist vulnerable groups, promoting health, and working with patient associations that support initiatives aimed at achieving a better quality of life, amongst other actions and commitments. In this regard, it works to achieve a sustainable balance between financial performance, social well-being and environmental conservation. www.grupoindukern.com For further information for the media: Daniel Leo (Atrevia) · Tlf. 667 631 624 · dleo@atrevia.com Andrea Guarino (Atrevia) · Tlf. 672 44 70 15 aguarino@atrevia.com Alba Alagón (Kern Pharma) · Tlf. 680 993 952 aalagon@kernpharma.com